Deals roundup

October 2008
Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p3
The article reports on the exclusive licensing agreement between Xenomics and Sequenom. Under the agreement, the latter will be given exclusive rights to use the patents of the former for the development of prenatal research and diagnostic products. Xenomics also has patents in other fields of medicine such as transplantation and infectious diseases.


Related Articles

  • Deals roundup.  // Medical Device Daily;9/23/2008, Vol. 12 Issue 203, p3 

    The article reports on the exclusive rights secured by Sequenom involving fundamental patent rights for digital polymerase chain reaction (PCR) technologies and methods under a licensing agreement with Genomic Nanosystems. The licensed rights include U.S. Patent Numbers 6,143,496 and 6,291,559...

  • Court report.  // Medical Device Daily;10/30/2009, Vol. 13 Issue 210, p6 

    The article reports that Xenomics complained Sequenom in the Supreme Court of the State of New York for fraudulent misrepresentation regarding the former's testing of the Down syndrome. It furthers that such conduct led to a license agreement of Xenomics with Sequenom with the former giving up...

  • Agreements.  // Diagnostics & Imaging Week;9/20/2007, Vol. 10 Issue 38, p5 

    The article reports on the licensing agreement signed by Xenomics, a developer of next-generation medical DNA diagnostic technologies, with French molecular diagnostics company, Ipsogen SAS. The agreement will provide Xenomics the rights to develop research and diagnostic products for the...

  • GE Healthcare completes its $860 million Vital Signs buy.  // Diagnostics & Imaging Week;11/6/2008, Vol. 11 Issue 45, p4 

    This article notes agreements reached between companies in the diagnostic imaging equipment industry. General Electric Co. subsidiary GE Healthcare completed the acquisition of diagnostic equipment company Vital Signs. Molecular diagnostic system and drug development company Clinical Data Inc....

  • TrovaGene Inc. Confirms It Has Regained Its Rights to Transrenal Technology for Non-Invasive Prenatal Testing and Cancer.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p352 

    The article reports that TrovaGene Inc. has regained its rights to transrenal technology for non-invasive prenatal applications and cancer by terminating its license agreement with Sequenom Inc. Thomas Adams, TrovaGene's chairman, says that the recovery gives them the opportunity to expand their...

  • NUVELO ASSIGNS PATENTS TO SEQUENOM.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p4 

    Reports on the patent assignment and license agreement signed by Nuvelo Inc. and SEQUENOM Inc. as of November 2003.

  • TrovaGene stops Sequenom, regains transrenal tech rights.  // Medical Device Daily;8/11/2011, Vol. 15 Issue 150, p3 

    The article reports on the termination of a license agreement between TrovaGene and Sequenom in 2011.

  • Sequenom patent and deal. Hodgson, John // Nature Biotechnology;Oct99, Vol. 17 Issue 10, p941 

    Reports that the U.S. Patent and Trademark Office in Washington D.C. has granted a patent on DNA sequencing for four branches of Sequenom Inc. Scope of the patent; Benefits of the patent to genetic analysis.

  • Noninvasive prenatal diagnosis of monogenic disease backed. PEDERSEN, AMANDA // Medical Device Daily;12/4/2008, Vol. 12 Issue 235, p1 

    The article discusses research on a noninvasive prenatal diagnosis of monogenic diseases. It references a study jointly conducted by Sequenom and the Chinese University of Hong Kong, published online in the early edition of the "Proceedings of the National Academy of Sciences." Identified...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics